Conference Coverage

VIDEO: Case for rivaroxaban & aspirin for PAD gets stronger

Publish date: March 21, 2018

 

REPORTING FROM ACC 18

COMPASS was sponsored by Bayer, the company that along with Janssen markets rivaroxaban. Dr. Anand has been a consultant to Bayer and Novartis. Dr. Beckman has been a consultant to Janssen and other pharmaceutical companies.

SOURCE: Anand SS et al. J Amer Coll Cardiol. 2018 Mar 11. doi: 10.1016/j.jacc.2018.03.008.

Pages

Recommended Reading

Recent upturn seen in stroke death rate
MDedge Internal Medicine
Metabolically healthy obese still at elevated cardiovascular risk
MDedge Internal Medicine
Older men benefit from vascular screening
MDedge Internal Medicine
New data prompt update to ACC guidance on nonstatin LDL lowering
MDedge Internal Medicine
Medtronic, others push forward with HTN renal artery denervation
MDedge Internal Medicine
Thrombosis risk is elevated with myeloproliferative neoplasms
MDedge Internal Medicine
VIDEO: Retinal infarctions get missed as stroke harbingers
MDedge Internal Medicine
Embracing Life’s Simple 7 slashes PAD risk
MDedge Internal Medicine
JAK inhibitors for RA: Is VTE risk overblown?
MDedge Internal Medicine
Viremic suppression linked to decreased MACE rate in patients with HCV-cirrhosis
MDedge Internal Medicine